miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
   PubMed Web of Science ®Google Scholar
• Han T, Xiang DM, Sun W, et al. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 2015;63:651–660.
   PubMed Web of Science ®Google Scholar
• Li XF, Chen C, Xiang DM, et al. Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. Hepatology. 2017;66:1934–1951.
   PubMed Web of Science ®Google Scholar
• Singh AK, Arya RK, Maheshwari S, et al. Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer. 2015;136:1991–2000.
   PubMed Web of Science ®Google Scholar
• Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012;21:283–296.
   PubMed Web of Science ®Google Scholar
• Mo DC, Jia RR, Zhong JH. Hepatic Resection Compared to Chemoembolization in Intermediate to Advanced-Stage HCC: a comment for moving forward. Hepatology. 2018;68(3):977–993.
   Google Scholar
• Bayoumi AS, Sayed A, Broskova Z, et al. Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci. 2016;17:356.
   PubMed Web of Science ®Google Scholar
• DeSano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. Aaps J. 2009;11:682–692.
   PubMed Web of Science ®Google Scholar
• Jiang C, Yu M, Xie X, et al. miR-217 targeting DKK1 promotes cancer stem cell properties via activation of the Wnt signaling pathway in hepatocellular carcinoma. Oncol Rep. 2017;38:2351–2359.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fu Y, Wu J, et al. The Diverse Mechanisms of miRNAs and lncRNAs in the Maintenance of Liver Cancer Stem Cells. Biomed Res Int. 2018;2018:8686027.
   PubMed Web of Science ®Google Scholar
• Li L, Tang J, Zhang B, et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut. 2015;64:156–167.
   PubMed Web of Science ®Google Scholar
• Ran RZ, Chen J, Cui LJ, et al. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway. Exp Cell Res. 2019;378:66–75.
   PubMed Web of Science ®Google Scholar
• Yang J, Sheng YY, Wei JW, et al. MicroRNA-219-5p Promotes Tumor Growth and Metastasis of Hepatocellular Carcinoma by Regulating Cadherin 1. Biomed Res Int. 2018;2018:4793971.
   PubMed Web of Science ®Google Scholar
• Xiang D, Cheng Z, Liu H, et al. Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 2017;65:1566–1580.
   PubMed Web of Science ®Google Scholar
• Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. Gut. 2018;67(9):1704–1715.
   Web of Science ®Google Scholar
• Xiang DM, Sun W, Zhou T, et al. Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. Gut. 2019;68:1858–1871.
   Web of Science ®Google Scholar
• Huang N, Lin J, Ruan J, et al. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012;586:884–891.
   PubMed Web of Science ®Google Scholar
• Fan Z, Duan J, Wang L, et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/beta-catenin signaling. Cancer Lett. 2019;450:132–143.
   PubMed Web of Science ®Google Scholar
• Sheng X, Sun X, Sun K, et al. Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells. Int J Oncol. 2016;49:1513–1524.
   PubMed Web of Science ®Google Scholar
• Chen JC, Chen MS. [Multidisciplinary therapeutic strategies for recurrence and metastasis of liver cancer]. Zhonghua Gan Zang Bing Za Zhi. 2016;24:327–329.
   PubMedGoogle Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–1098.
   PubMed Web of Science ®Google Scholar
• Wang D, Fu L, Sun H, et al. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015;149:1884–1895 e1884.
   PubMed Web of Science ®Google Scholar
• Kai K, Dittmar RL, Sen S. Secretory microRNAs as biomarkers of cancer. Semin Cell Dev Biol. 2018;78:22–36.
   PubMed Web of Science ®Google Scholar
• Afonso MB, Rodrigues PM, Simao AL, et al. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med. 2016;5(3).
   Google Scholar
• Gul IS, Hulpiau P, Saeys Y, et al. Evolution and diversity of cadherins and catenins. Exp Cell Res. 2017;358:3–9.
   PubMed Web of Science ®Google Scholar
• Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer. 2000;36:1607–1620.
   PubMed Web of Science ®Google Scholar
• Canel M, Serrels A, Frame MC, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.
   PubMed Web of Science ®Google Scholar
• Azizi R, Salemi Z, Fallahian F, et al. Inhibition of didscoidin domain receptor 1 reduces epithelial-mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines. J Cell Physiol. 2019;234:19539–19552.
   Web of Science ®Google Scholar
• Luo T, Wang L, Wu P, et al. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?. Neoplasma. 2017;64:693–699.
   PubMed Web of Science ®Google Scholar
• Tamura S, Isobe T, Ariyama H, et al. Ecadherin regulates proliferation of colorectal cancer stem cells through NANOG. Oncol Rep. 2018;40:693–703.
   PubMed Web of Science ®Google Scholar
• Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res. 2013;43:147–154.
   PubMed Web of Science ®Google Scholar